Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPEC-AA: Anti-convulsants vs Anti-depressants for Chronic Pain
NCT04441034Phase 4Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2022
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chronic pain (3 arms), sponsored by Stanford University. Primary endpoint: Change in Pain Intensity at 6 months. Started Apr 2022; status: recruiting.
02
Conditions
chronic pain
Beyond the preview
Go deeper on NCT04441034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04441034.